Planview and UiPath Partner to Optimize Test Automation with Value Stream Management Capabilities
29.3.2023 16:00:00 EEST | Business Wire | Press release
Planview, the leading platform for connected work from portfolio planning to delivery, today announced a new strategic collaboration with UiPath (NYSE: PATH), a leading enterprise automation software company. The integration is designed to fuse the UiPath Business Automation Platform with the Planview market-shaping Value Stream Management (VSM) solution Planview® Tasktop Hub. By combining UiPath Test Suite and VSM, teams can improve the automation of repetitive and time-consuming tasks, reduce manual errors, and accelerate the delivery of their products.
“Our collaboration with UiPath is a game-changer for technology leaders looking to solve efficiency and visibility challenges,” said Louise K. Allen, Chief Product Officer, Planview. “Rapid and continuous automation testing is no longer a nice-to-have; it’s critical to accelerating digital transformation and fostering the future of connected work. A recent Planview report found that bottlenecks frequently happen at the end of the release process, with 40% of end-to-end delivery time spent on software testing and release activities. This integration will offer visibility and control over the entire software development lifecycle, enabling teams to optimize workflows for better outcomes.”
Planview Tasktop Hub enables UiPath to integrate with more than 40 of the most popular application lifecycle management (ALM) tools on the market, such as Azure DevOps, Jira, and ServiceNow. Teams can now apply production-grade test automation on modern and legacy applications. The combined solution also offers the ability to automate testing and other software delivery tasks, enabling teams to achieve faster and more reliable delivery while freeing up resources to focus on more strategic and high-value activities.
“Together with Planview, CIOs and IT leaders can achieve software testing outcomes faster at a lower cost with our intuitive and scalable testing solutions included in the market’s only end-to-end automation platform,” said Dr. Gerd Weishaar, Senior Vice President of Product Management at UiPath. “Organizations can leave disparate legacy testing tools behind and consolidate on the UiPath platform to modernize how teams manage and execute delivery of their product.”
Planview Tasktop Hub enables CIOs and transformation leaders to track value flow to business outcomes by combining the power of best-of-breed toolchains into a seamless tech stack that optimizes productivity, eliminates bottlenecks, improves time-to-market and reduces lost revenue. The solution implements the Flow Framework®, created by the company’s Chief Technology Officer, Dr. Mik Kersten. Planview’s VSM solution was recently named a leader in The Forrester Wave™ Value Stream Management Q4 report, receiving the highest possible scores in the criteria of third-party integration, VSM dashboard, end-user experience, analytic capabilities, KPI tracking, product vision, and innovation roadmap.
For more information on Planview’s market-leading portfolio and work management solutions, visit: www.planview.com. To learn more about the UiPath Business Automation Platform visit: www.uipath.com.
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005208/en/
Contact information
Media Relations for Planview
Natalie Reina
Director of Corp Comms
natalie.reina@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom